Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02129387 · ClinicalTrials.gov registry record
EEG & Behavioral Predictors of Changes in Smoking Trajectories in Young Light Smokers
A clinical trial, sponsored by Southern Illinois University Carbondale.
- Completed
- Registry status
- 115
- Enrollment target
NCT02129387: Completed study, sponsored by Southern Illinois University Carbondale.
NCT02129387 is a clinical trial that has completed, run by Southern Illinois University Carbondale. The registered enrollment target is 115 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02129387 has completed, sponsored by Southern Illinois University Carbondale.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
Study Summary
The purpose of the proposal is to identify new predictors of smoking progression in young light smokers (YLS: 18-25 years \& cpd \< 5) using an 18-month longitudinal design and to relate these predictors of progression to the genetic profile most highly associated with smoking progression. A number of novel predictors will be assessed in 128 YLS. Predictors will include individual differences (IDs) in EEG, reward sensitivity, attentional performance, and mood during abstinence and in response to standardized and to self-selected acute nicotine doses (ANIC), as well as genetically influenced affective traits, and smoking history. The associations of a compelling genetic functional variant polymorphism, rs16969968, in the alpha5 nicotinic receptor subunit will also be related to smoking progression and the novel predictors. The study is expected to provide insights into IDs in mechanisms and predictors that contribute to smoking trajectories in YLS and thereby lead to targeted pharmacotherapy and behavioral interventions for at-risk YLS.
Primary Outcome
Change in smoking and salivary cotinine concentration from baseline to 18 months will be assessed at 3 month intervals-- 3, 6, 9, 12, 15, and 18 months after initial assessments.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2014-04 |
| Est. Completion | 2021-11-30 |
What the finished NCT02129387 record still lists
NCT02129387 is an observational study that tracks outcomes without assigning an intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02129387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02129387 about?
NCT02129387 is a clinical study titled "EEG & Behavioral Predictors of Changes in Smoking Trajectories in Young Light Smokers". The purpose of the proposal is to identify new predictors of smoking progression in young light smokers (YLS: 18-25 years \& cpd \< 5) using an 18-month longitudinal design and to relate these predictors of progression to the genetic profile most highly associated with smoking progression. A number ...
What is the current status of trial NCT02129387?
This trial is currently completed. The enrollment target is 115 participants. The study started on 2014-04. Estimated completion is 2021-11-30.
Who is sponsoring clinical trial NCT02129387?
This trial is sponsored by Southern Illinois University Carbondale, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia